Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain

By Reuters News

By Bhanvi Satija

- Flagship Pioneering is opening its first lab for creating companies outside the United States, putting £100 million ($131.94 million) behind a new UK-based effort to fund and build AI-driven biotech companies, the venture firm said on Monday.

The move is a first for a firm that has created more than 130 companies, including Moderna MRNA.O, and operated only from the United States for more than 25 years.

Flagship's move comes after three years of groundwork in Britain. The company opened its London office in 2023 near the Francis Crick Institute in King’s Cross and its local team has since built partnerships with academia, government and regulatory groups.

"We concluded that this might well be the right next step in our evolution," Noubar Afeyan, founder and CEO of the venture firm, told Reuters in an interview. The Flagship Origination lab will be anchored at the firm's London office.

Afeyan said that the firm will not buy into existing companies, and instead plans to "cast a wide net" for partnerships with universities, corporations and funders.

It hopes its £100 million will attract £500 million or more from partners. Flagship expects to recruit about 50 scientist-entrepreneurs and operators in Britain initially.

AI will run through every stage of the lab’s work, from invention to clinical trials, said Afeyan, who is also the chairman of Moderna.

Afeyan said the country's main draw is the National Health Service and the patient data it has gathered, which lets researchers begin with real-world evidence to find disease targets before developing drugs.

Flagship companies are already testing that approach, including drug developer Generate Biomedicines GENB.O , which completed an early-stage trial of an AI-designed drug for asthma in Manchester.

Afeyan cautioned that the use of AI in the field is still early.

"We're in an age where I think AI's most fundamental contribution in the first instance will be to shed a light on actually what's happening mechanistically in diseases," he said.

($1 = 0.7579 pound)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.